Key Points
- CEO insider sale: James Mackin sold 17,887 shares on March 3 at an average of $37.78 (~$675,771), reducing his stake by 1.85% to 947,275 shares, and several other senior insiders also sold on March 2–4 — a clustered selling wave that can be viewed negatively by the market.
- Recent results: Artivion beat expectations with Q results of $0.17 EPS versus $0.14 est. and $118.3M revenue (up 19.2% YoY), supporting the company’s growth narrative and a consensus forecast of about $0.37 EPS for the fiscal year.
- Market positioning: The stock trades near $38 with a market cap of ~$1.84B and a high P/E (~192); institutional ownership is about 86% and analysts show a consensus "Moderate Buy" with an average target around $48.97.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean Holloway sold 3,843 shares of the firm's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $145,188.54. Following the completion of the transaction, the senior vice president directly owned 194,057 shares in the company, valued at $7,331,473.46. This trade represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Artivion Stock Down 1.6%
Shares of NYSE:AORT traded down $0.60 during midday trading on Thursday, hitting $37.90. 24,755 shares of the company's stock were exchanged, compared to its average volume of 409,237. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The company has a market cap of $1.81 billion, a PE ratio of 189.51 and a beta of 1.60. The stock has a 50 day moving average price of $41.42 and a 200-day moving average price of $42.92.
Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company's revenue for the quarter was up 19.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.
Institutional Trading of Artivion
Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its stake in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company's stock valued at $50,228,000 after acquiring an additional 748,119 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Artivion in the 4th quarter worth approximately $746,000. Susquehanna Portfolio Strategies LLC raised its holdings in shares of Artivion by 21.5% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company's stock worth $1,849,000 after purchasing an additional 7,186 shares during the period. Occudo Quantitative Strategies LP purchased a new position in Artivion in the fourth quarter valued at approximately $248,000. Finally, Millennium Management LLC grew its holdings in Artivion by 1.0% during the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company's stock valued at $4,188,000 after purchasing an additional 893 shares during the period. Institutional investors own 86.37% of the company's stock.
Analyst Ratings Changes
AORT has been the subject of several recent analyst reports. Weiss Ratings upgraded shares of Artivion from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, February 20th. Oppenheimer restated an "outperform" rating and set a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Citizens Jmp increased their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a "market outperform" rating in a research note on Friday, November 7th. Needham & Company LLC reissued a "buy" rating and set a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Finally, Wall Street Zen lowered Artivion from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $48.97.
Read Our Latest Analysis on Artivion
More Artivion News
Here are the key news stories impacting Artivion this week:
- Positive Sentiment: Management will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference (virtual fireside chat) — a near‑term opportunity for management to update guidance, commercialization progress or product milestones that could re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
- Positive Sentiment: Recent quarter (Feb. 12) beat EPS and revenue estimates and showed ~19% YoY revenue growth — supports the growth story and underpins analyst conviction. MarketBeat - Artivion Earnings Summary
- Positive Sentiment: Large institutional buyers have been increasing exposure (notably Invesco’s sizable Q4 add and other funds raising positions), which can provide steadier bid support and signal professional investor confidence. MarketBeat - Institutional Activity
- Neutral Sentiment: Analyst coverage remains constructive overall (consensus "Moderate Buy", average target ≈ $49) — helpful for demand but much of this view appears priced in. MarketBeat - Analyst Ratings
- Neutral Sentiment: Media pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite; these bolster narrative but are not immediate catalysts on their own. Portfolio Expansion Article
- Negative Sentiment: A cluster of senior insider sales from March 2–4 (including CEO James Mackin, EVP Lance Berry, multiple SVPs and the CAO) — markets often treat concentrated insider selling as a near‑term negative signal even though insiders retain large stakes; monitor whether additional sales or explanations (planned sales, tax/liquidity needs) surface. Insider Trades Alert
Artivion Company Profile
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
